GlassScriptPrepare for your visit
Nabil F Saba
Medical Oncology · Atlanta, GA · NPI 1558479188
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$224,880.25
in general payments reported to CMS, 2019-2025 · $89K in 2025
The $89K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Who reported paying
General payments only, top 6 by amount.
- Merck Sharp & Dohme LLC $69,716.21
- Dr.Reddy'S Laboratories,INC. $33,048.12
- Glaxosmithkline, LLC. $27,403.19
- Exelixis INC. $26,318.69
- Emd Serono Research & Development Institute, INC. $11,250.00
- Eisai INC. $11,020.00
Drugs and devices associated with these payments
Lenvima Loqtorzi Keytruda Tivdak Papzimeos Rybrevant Imfinzi Fotivda Zusduri Cabometyx Trodelvy Udenyca
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Nabil Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/24795/nabil-f-saba